

Subject Index

- abandonment, fear 87
- acidification 76
- acquired immunodeficiency syndrome (AIDS) 20f.
 - associated conditions 39
 - in Central Europe 1ff.
 - CMV infection 59
 - development 17
 - epidemic 6, 11, 27, 56, 75
 - etiology 6ff.
 - HIV-seropositive subjects 46
 - Hodgkin's disease 38, 40f.
 - immunological mechanisms 17
 - life expectancy 29
 - malignant lymphomas 37ff.
 - neoplastic complications 37
 - non-Hodgkin's lymphomas 13, 38ff.
 - pathogenesis 8, 17
 - patients, family members 75f.
 - psychosocial issues 84
 - sexual partners 86, 91f.
 - related complex (ARC) 20f., 39f.
 - complications 18
 - neoplasias 6
 - tumors 71, 84
 - Swiss Group 71
 - risk groups 28
 - statistics 1
 - current infection rate 4
- adriamycin 34
- α -interferon 34
- alkalinization 76
- alkylating agents 54
- angioliopoma 11
- antibody, neutralizing 20
- antigenic stimulation, chronic 17
- ataxia telangiectasia 6, 54, 69
- autoantibodies to T-cells 18
- autoimmune responses by HIV-proteins 10
- autopsy rooms 79
- azathioprine 54
- azidothymidine (AZT) 35
- behaviour, high-risk 85
- biopsies, lymph node 58
- bleomycin 34
- blood transfusion 27, 47, 75
- B symptoms 57f.
- cancer 90
 - incidence 11
 - oral 11
 - rectal 11
 - skin 7
- carcinoma
 - anal 12, 37, 71
 - anorectal 71
 - cloacogenic 56
 - gastrointestinal 71
 - genital 12
 - hepatocellular 12
 - of the lung 11
 - of the mouth 56
 - nasopharyngeal 12, 56
 - testicular 11, 56, 72
 - of the tongue 37, 56, 71
- cells
 - antigen presenting (APC) 8
 - HIV-infected 9
 - killer 8
 - natural (NK) 18, 21
 - suppressor, activity 18, 21
- chemotherapy 34, 69
 - aggressive combined 58, 93
 - combined with antiretroviral drugs 59
 - infectious complications 34
 - and NHL 55
- childbearing 92
- coagulation intravascular disease 41f.
- colony stimulating factors (CSF) 59

- communication 92
- cooperative trials, prospective 93
- coping strategy 87
- corticosteroids 54
- cryotherapy 34
- cyclosporin A 54
- cytomegalovirus (CMV) 12, 17
- cytotoxicity, antibody dependent cell-mediated (ADCC) 10, 18, 21

- damage, central nervous system, HIV-associated 10
- death-fears 88
- defect, immunological 17
- denial, adaptive 88, 90f.
- dental office 79
- desiccation 76
- diagnostic procedures 80
- dialysis 79
- diethyldithiocarbamate (DTC) 22
- dinitrochlorobenzene (DNCB) 34
- disclosure of diagnosis 86
- disease
 - autoimmune 54f., 70
 - central nervous system 88
 - immunodeficiency 54
 - inflammatory 54f.
- disinfectants 76f.
- drug abusers 47

- Epstein-Barr virus (EBV) 12, 17
- etoposid (VP16) 34

- fear of abandonment 87
 - death 88
 - isolation 87
 - loss 88
 - separation 88
- France 46
- future prospects 3, 93

- genes, regulatory 7
- germicides 76f.
- γ -interferon 8
- guilt 91

- health care workers 77f.
- health care situations, high-risk 79
- heat-inactivation 76
- hemophiliacs 27, 75
- herpes simplex virus (HSV) 17
- heterosexual contact 47
 - population 2
- histocompatibility complex, major (MHC) 9

- Hodgkin's disease 11, 47, 63, 70f.
 - AIDS-related 58
 - extranodal manifestations 43
 - mixed cellularity-type 65
 - in patients with HIV-infection 57
- homosexuality 47
- homosexuals 2, 38
 - AIDS-associated Kaposi's sarcoma 28
 - chronic active infections 17
 - CMV-infection 12
 - HIV-positive 71
 - Kaposi's sarcoma 27, 75
 - malignant lymphoma 38
 - pneumocystis carinii pneumonia 27, 75
- HTLV-IV, pathogenic potential 7
- human immunodeficiency virus (HIV)
 - antiviral immune responses 10
 - classification 6
 - genome 7f.
 - inactivation 75ff.
 - infected cells 9
 - infection
 - B-cell hyperplasia 13
 - immunological characteristics 17
 - immunotherapy 17
 - and malignant lymphoma 54ff., 63ff.
 - occupationally acquired 78
 - risk for exposure 80
 - and tumors 11
 - proteins 7f.
 - seropositive subjects 21, 46, 90
 - childbearing 92
 - and Kaposi's sarcoma 12
 - transmission 75, 85
 - from health care workers to patient 81
- hypergammaglobulinemia 18f.

- immune
 - activation 17
 - antiviral responses 10
 - chronic stimulation 54
- immunity, defective, cell-mediated 27
- immunodeficiency 54, 69
 - congenital 55
 - T-cell 21, 69
- immunomodulation therapy 22
- immunorestorative therapy 22
- immunosuppression, chemical 54
- infections
 - activation of latent DNA-virus 12
 - chronic active 17
 - control 78
 - HIV, incidence 93
 - opportunistic 7, 18, 27, 37, 40ff.

- infections
 - treatment 35
- inflammatory disorders, chronic 70
- intravenous drug addicts 2, 27, 38, 75
 - chronic active infections 17
 - Kaposi's sarcoma 3
 - malignant lymphomas 38
- interleukin 2, 8
- isolation, fear 87
- Italy 37

- Kaposi's sarcoma 6, 11 f., 18, 20, 37, 55, 69, 71, 93
 - AIDS-related 27 f.
 - risk groups 28 f.
 - treatment 34
 - CMV-associated 12
 - differential diagnosis 33
 - endemic 12
 - epidemic 28
 - etiology 33
 - HIV-related 12
 - in intravenous drug abusers 3
 - and malignant lymphoma 56
 - in organ transplant recipients 12
 - sporadically occurring 12

- laboratories 80
- LAV-2, pathogenic potential 7
- leukemia
 - acute 69
 - non-lymphatic 69 f.
 - prolymphocytic 56
- lymphadenopathy
 - angioimmunoblastic 40
 - HIV-associated 58
 - lymph node biopsies 58
 - persistent generalized (PGL) 38 f., 58
- lymphocyte, T-, cytotoxic (CTL) 18, 21
- lymphokine 8
- lymphoma
 - AIDS-related 56
 - management 58
 - malignant 63, 71, 90
 - anorectal 59
 - Burkitt-type 12, 37, 42, 57, 65
 - centroblastic 65
 - centrocytic 65
 - EBV-induced 18, 57
 - and HIV-infection 54 f., 57 f., 63 f.
 - immunoblastic 6, 37, 65
 - and Kaposi's sarcoma 56
 - lymphoblastic 37, 65
 - in patients with AIDS 38
 - non Hodgkin's (NHL) 6, 11, 13, 37, 47, 55, 69 f., 93
 - B-Cell 6, 13, 18, 70
 - CNS-origin 37 f., 42, 56
 - differential diagnosis 59
 - extranodal location 37, 39, 43, 56
 - high-grade 54
 - incidence 72
 - initial site 39 f.
 - primary, of the brain 11
 - thymic 12
- malignancy
 - AIDS-related 55 f.
 - hematological 46
 - high-grade 63
 - intermediate-grade 63
 - low 63
 - melanoma, malignant 71
 - morgues 79
 - mortuaries 79
 - multiple myeloma 56

- neoplasia
 - hematological 46
 - HIV-related 46

- oncoviruses, human 11
- organ involvement 64, 66

- papilloma virus, human 12
- persistent generalized lymphadenopathy 38 f.
- plasmacytoma 64 f.
 - solitary 56
- pneumonia, pneumocystis carinii 27
- population, sexually promiscuous 11
- potential risk, persons exposed to 5
- precautions 75 f.
 - universal 81
- prevention 93
 - primary 84
- professionals, allied to health care 77 f.
- psychosocial impact 86

- radiotherapy 69
- recommendations to persons exposed to potential risk 5

- safety 75 f.
- self esteem 86
- separation, fears 88
- serum immunoglobulins 66
- sexual partners 86, 91

- suicidal thoughts 88
- summary 93
- survival, median 93
- Switzerland 69, 71
- syndrome, Wiskott-Aldrich 6, 69
- T-cell
 - depletion 18, 57
 - helper 8
 - immunodeficiency 57
 - perturbed function 18
- therapeutic strategies, alternative 93
- therapy
 - antiretroviral 35, 59
 - immunomodulatory 22 ff., 35
 - immunorestorative 22 ff., 60
 - immunosuppressive 6, 27, 54 f.
 - non toxic 24
- T-lymphocytic, cytotoxic (CTL) 8
- transplant recipients
 - and Kaposi's sarcoma 12
 - organ 55
 - renal 6, 27, 69
- treatment 64, 67
 - cosmetic 87
- trends, certain population groups 2
- tumors
 - DNA-virus associated 12
 - in HIV-infections 11
 - "secondary" 69
 - skin 69
- uncertainty in disease course 87
- vinblastine 34
- viral effects
 - indirect 10
 - on HIV infected cells 9
- workers, health care 77 f.